Lokit Healthcare, Gangstem Biotech, Apures, and Others Sign Business Agreement

[Asia Economy Reporter Hyungsoo Park] Rokit Healthcare, a specialist company in ultra-personalized organ regeneration, announced on the 6th that it has signed a business agreement with biotechnology company Apures and stem cell company Gangstem Biotech.

Rokit Healthcare is developing artificial organ and skin/cartilage regeneration technologies based on artificial intelligence (AI), bioprinting, and bioink technologies. Through strategic alliances, it aims to expand its business areas and secure differentiated capabilities in the regenerative treatment field.

Founded in 2001, Apures is a bio company researching xenogeneic organs and micropigs, which are similar to the human body. Through the business agreement, they will collaborate on ▲exchange of know-how on 3D bioprinting technology and decellularization/recellularization technology ▲cooperation on single-cell transcriptome and genome analysis ▲supply of materials and resources from micropigs.

Choi Seondeok, CEO of Apures, said, "The connection from the preclinical research of the kidney regeneration platform with Rokit Healthcare has extended to the single-cell transcriptome research of its subsidiary Rokit Genomics," adding, "We plan to conduct not only the development of xenogeneic cell therapeutics and new drugs based on primary cells using Rokit Genomics' single-cell transcriptome technology but also non-clinical CRO services."

Rokit Healthcare will develop decellularization and recellularization technologies together with Apures, which has researched xenogeneic organs and micropigs most similar to the human body for 20 years. It is expected to expand its regenerative treatment business area, including collaboration on pig-derived bioink development.

Rokit Healthcare also signed a business agreement with stem cell therapeutic developer Gangstem Biotech for the development of biomaterials. The two companies will continue cooperation on ▲development of bio-implant materials and exchange of know-how on decellularization and recellularization technologies ▲biomaterial research for advanced regenerative medicine and advanced biopharmaceutical development ▲optimization research of recellularization protocols using Dr. Invivo Niche Regen.

Na Jongcheon, CEO of Gangstem Biotech, said, "There is great interest in bio-implant materials necessary for pipeline applications such as skin organoids," adding, "We will accelerate research and material studies using Dr. Invivo Niche Regen in collaboration with Rokit Healthcare."

Yoo Seokhwan, CEO of Rokit Healthcare, explained, "The platform for skin and cartilage regeneration has completed technology development and entered the commercialization stage," adding, "We developed Dr. Invivo Niche Regen because we judged that new methods and platforms are needed for organ regeneration."

He continued, "We will collaborate with bio companies to develop various solutions and strengthen research capabilities to serve as an organ regeneration platform."

Through Dr. Invivo Niche Regen, Rokit Healthcare is also challenging organ regeneration of the kidney, liver, heart, and other organs. In terms of global distribution contracts, it is rapidly increasing the number of commercialization countries, recently exporting the skin organ regeneration platform to Alkem, one of the top five pharmaceutical companies in India.

This content was produced with the assistance of AI translation services.